Abstract
(Abstracted from JAMA 2018;320(6):557–565) Cell-free DNA (cfDNA) tests are increasingly offered to women at increased risk of trisomy 21 to decrease the number of required invasive fetal karyotyping procedures and their associated miscarriages. The effect of this strategy has not been evaluated prospectively when compared with invasive diagnostic testing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have